GT201200265A - Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar - Google Patents

Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar

Info

Publication number
GT201200265A
GT201200265A GT201200265A GT201200265A GT201200265A GT 201200265 A GT201200265 A GT 201200265A GT 201200265 A GT201200265 A GT 201200265A GT 201200265 A GT201200265 A GT 201200265A GT 201200265 A GT201200265 A GT 201200265A
Authority
GT
Guatemala
Prior art keywords
peptide
coupled
amiloid
viruses
beta
Prior art date
Application number
GT201200265A
Other languages
English (en)
Inventor
Ulrich Peter
Baer Katja
Imbert Georges
Hoellinger Marie-Jose
Riviere Marie-Emmanuelle
Graf Ana
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201200265A publication Critical patent/GT201200265A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES QUE COMPRENDEN UNA CONSTRUCCIÓN QUE COMPRENDE EL PÉPTIDO A-BETA1-6 Y UN AUXILIAR FARMACÉUTICAMENTE ACEPTABLE, PARA EL TRATAMIENTO DE PACIENTES QUE SUFREN DE DEMENCIA, EN PARTICULAR DEMENCIA DEL TIPO ALZHEIMER. EN UNA MODALIDAD, LA CONSTRUCCIÓN QUE CONTIENE EL PÉPTIDO A-BETA1-6 CONSISTE DE UNA PARTÍCULA SIMILAR A VIRUS (VLP) DEL BACTERIÓFAGO DE ARN QBETA QUÍMICAMENTE ACOPLADO A DICHO PÉPTIDO A-BETA1-6.
GT201200265A 2010-03-29 2012-09-26 Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar GT201200265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
GT201200265A true GT201200265A (es) 2014-03-14

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200265A GT201200265A (es) 2010-03-29 2012-09-26 Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar

Country Status (23)

Country Link
US (4) US20130011431A1 (es)
EP (1) EP2552489A1 (es)
JP (2) JP6088422B2 (es)
KR (1) KR20130018407A (es)
CN (2) CN104436212A (es)
AR (1) AR080810A1 (es)
AU (1) AU2011234656B2 (es)
BR (1) BR112012024708A2 (es)
CA (1) CA2793580A1 (es)
CL (1) CL2012002685A1 (es)
CO (1) CO6630127A2 (es)
EC (1) ECSP12012180A (es)
GT (1) GT201200265A (es)
IL (1) IL221540B (es)
MA (1) MA34084B1 (es)
MX (1) MX2012011340A (es)
NZ (1) NZ601729A (es)
PE (1) PE20130642A1 (es)
RU (1) RU2603486C2 (es)
SG (2) SG183806A1 (es)
TN (1) TN2012000431A1 (es)
TW (2) TW201138805A (es)
WO (1) WO2011120924A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2953381T3 (es) 2014-04-29 2023-11-13 Advantage Therapeutics Inc Tratamiento y prevención de la enfermedad de Alzheimer (AD)
CN106659738B (zh) * 2014-04-29 2021-02-09 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
NZ601729A (en) 2013-10-25
AU2011234656B2 (en) 2013-08-01
CN102834118A (zh) 2012-12-19
PE20130642A1 (es) 2013-06-19
CL2012002685A1 (es) 2013-01-25
JP6088422B2 (ja) 2017-03-01
RU2012145734A (ru) 2014-05-10
US20140348871A1 (en) 2014-11-27
TN2012000431A1 (en) 2014-01-30
MX2012011340A (es) 2012-11-16
US20160101167A1 (en) 2016-04-14
IL221540B (en) 2018-11-29
KR20130018407A (ko) 2013-02-21
JP2013523682A (ja) 2013-06-17
RU2603486C2 (ru) 2016-11-27
AU2011234656A1 (en) 2012-10-11
EP2552489A1 (en) 2013-02-06
SG10201505374TA (en) 2015-08-28
SG183806A1 (en) 2012-10-30
AR080810A1 (es) 2012-05-09
BR112012024708A2 (pt) 2016-06-07
US20130011431A1 (en) 2013-01-10
MA34084B1 (fr) 2013-03-05
CN104436212A (zh) 2015-03-25
TW201138805A (en) 2011-11-16
US20150297692A1 (en) 2015-10-22
ECSP12012180A (es) 2012-10-30
WO2011120924A1 (en) 2011-10-06
JP2017008035A (ja) 2017-01-12
CO6630127A2 (es) 2013-03-01
TW201618806A (zh) 2016-06-01
CA2793580A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
GT201200265A (es) Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar
DOP2019000201A (es) Compuestos inhibidores del vih
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
DOP2016000233A (es) MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
PH12018500573A1 (en) Hepatitis b core protein modulators
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
AR091395A1 (es) Aminotriazolopiridina para usar el tratamiento de la inflamacion y composiciones farmaceuticas de la misma
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CU20150071A7 (es) Composición de liberación demorada que comprende biguanida
CU24504B1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol y un proceso que incluye un paso de granulación para preparar el mismo
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
HN2011000864A (es) Particulas inhalables que comprenden tiotropio
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CR20140527A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MY194140A (en) Isoxazolidine derivatives
ZA202002129B (en) Oral bendamustine formulations
EA201890160A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
EA201890334A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с